This activity is jointly provided by Haymarket Medical Education and Renal & Urology News.
Primary focal segmental glomerulosclerosis (FSGS), commonly found in ESRD patients, is one of the leading causes of primary glomerular disease. It is especially important to distinguish primary and secondary FSGS to spare patients from undergoing unnecessary and potentially harmful immunosuppressive therapy. But making that distinction is challenging, and many nephrologists are unclear how to do this.
Statement of Need
Primary focal segmental glomerulosclerosis (FSGS) is a common glomerular disease in adults and ranks among the top causes of a primary glomerular disease causing end-stage renal disease (ESRD). Primary FSGS is, however, a diagnosis of exclusion that is reached after known causes of FSGS have been ruled out. The distinction between primary versus secondary FSGS is not always obvious, resulting in a number of patients with secondary FSGS undergoing unnecessary and potentially harmful immunosuppressive therapy.
This activity has been designed to meet the needs of nephrologists and supporting clinicians who treat patients with FSGS.
After completing the activity, the participant should be better able to:
Explain the differences between primary and secondary FSGS
Categorize patients according to whether they have nephrotic-range proteinuria or nephrotic syndrome
Formulate the most appropriate management strategy for individual patients with FSGS
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest in an effort to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, HME seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HME is committed to providing its learners with highquality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Fernando C. Fervenza, MD, PhD Professor of Medicine Mayo Clinic Rochester, Minn.
Fernando C. Fervenza, MD, PhD, reports having received grants and research support from Genentech, QuestCor, Biogen Idec, and Sanofi.
Richard J. Glassock, MD Emeritus Professor of Medicine Geffen School of Medicine, School at UCLA Los Angeles, CA
Richard J. Glassock, MD, reports no relevant financial relationships.
Sanjeev Sethi, MD, PhD Professor of Laboratory Medicine & Pathology Mayo Clinic Rochester, Minn.
Sanjeev Sethi, MD, PhD, reports no relevant financial relationships.
Planners and Staff Disclosures
HME staff involved in the planning and content review of this activity has no relevant financial relationships to disclose.
Renal & Urology News staff involved in the planning of this activity has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Haymarket Medical Education (HME) and Renal & Urology News. Haymarket Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
HME designates this enduring material for a maximum of 1.00 AMA PRA
Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. HME and Renal & Urology News do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME and Renal & Urology News. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Haymarket Medical Education or Renal & Urology News. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Renal & Urology News. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
There are no fees for participating in and receiving CME credit for this activity. During the period July 2014 through July 2015, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the post-test and submit it online, and 4) complete the evaluation form online. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.